Adoptive T-cell Immunotherapy of Cancer Using Chimeric Antigen Receptor-Grafted T Cells

David Marc Davies, John Maher

Research output: Contribution to journalLiterature reviewpeer-review

14 Citations (Scopus)


Harnessing the power of the immune system to target cancer has long been a goal of tumor Immunologists. One avenue under Investigation is the modification of T cells to express a chimeric antigen receptor (CAR). Expression of such a receptor enables T-cell specificity to be redirected against a chosen tumor antigen. Substantial research in this field has been carried out. incorporating a wide variety of malignancies and tumor-associated antigens Ongoing investigations will ensure this area continues to expand at a rapid pace. This review will explain the evolution of CAR technology over the last two decades in addition to detailing the associated benefits and disadvantages The outcome of recent phase I clinical trials and the Impact that these have had upon the direction of future research in this field will also be addressed
Original languageEnglish
Pages (from-to)165 - 178
Number of pages14
JournalArchivum Immunologiae et Therapiae Experimentalis
Issue number3
Publication statusPublished - Jun 2010


Dive into the research topics of 'Adoptive T-cell Immunotherapy of Cancer Using Chimeric Antigen Receptor-Grafted T Cells'. Together they form a unique fingerprint.

Cite this